Faculty: Angela Baldwin, MD, MPH, FCAP
Introducing the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic test that helps you detect the Folate Receptor α (FOLR1) biomarker in patients with epithelial ovarian cancer (EOC). By testing for FRα expression, you can help identify 35% of patients with EOC that may benefit from a promising FRαtargeted therapy; ELAHERETM (mirvetuximab soravtansine).
This comprehensive short course aims to support pathologists with clinical training to better understand FRα biology and scoring of this novel IHC marker for EOC samples.
VENTANA FOLR1 (FOLR1-2.1) RxDx Assay is a qualitative immunohistochemical assay using mouse monoclonal anti-FOLR1, clone FOLR1-2.1, intended for use in the assessment of folate receptor alpha (FOLR1) protein in formalin-fixed, paraffin-embedded epithelial ovarian, fallopian tube, or primary peritoneal cancer tissue specimens by light microscopy.
FOLR1 expression clinical cut-off is ≥ 75% viable tumor cells (TC) with membrane staining at moderate and/or strong intensity levels.
Practicing academic and community pathologists, and pathologists in training
the end of the presentation attendees should be able to:
The webinar is possible through Roche. This content is not available for continuing medical education. If you continue to register, you are acknowledging that your information will be shared with the company, including your name, degrees, institution, NPI number, mailing address, email address, and phone number. USCAP has no control over the use of this information.
The information presented represents the opinion of the presenters and is not necessarily the view of USCAP. USCAP does not endorse the products or services. The webinar is possible through Roche. This activity is not available for CME.